Abstract
The influence of autophagy inhibition on radiation sensitivity was studied in human breast, head and neck, and non–small cell lung cancer cell lines, in cell lines that were either wild type or mutant/null in p53, and in cells where p53 was inducible or silenced. Whereas ionizing radiation promoted autophagy in all tumor cell lines studied, pharmacological inhibition of autophagy and/or genetic silencing of autophagy genes failed to influence sensitivity to radiation in p53 mutant Hs578t breast tumor cells, HN6 head and neck tumor cells, and H358 non–small cell lung cancer cells. The requirement for functional p53 in the promotion of cytoprotective autophagy by radiation was confirmed by the observation that radiation-induced autophagy was nonprotective in p53 null H1299 cells but was converted to the cytoprotective form with induction of p53. Conversely, whereas p53 wild-type HN30 head and neck cancer cells did show sensitization to radiation upon autophagy inhibition, HN30 cells in which p53 was knocked down using small hairpin RNA failed to be sensitized by pharmacological autophagy inhibition. Taken together, these findings indicate that radiation-induced autophagy can be either cytoprotective or nonprotective, a functional difference related to the presence or absence of function p53. Alternatively, these findings could be interpreted to suggest that whereas radiation can induce autophagy independent of p53 status, inhibition of autophagy promotes enhanced radiation sensitivity through a mechanism that requires functional p53. These observations are likely to have direct implications with respect to clinical efforts to modulate the response of malignancies to radiation through autophagy inhibition.
Footnotes
- Received August 6, 2014.
- Accepted February 9, 2015.
S.C. and K.S. contributed equally to this work.
This research was supported in part by the National Institutes of Health National Cancer Institute [Grants R01-CA171101 (to S.V.T. and F.M.T.) and 5R21-CA171974 (to D.A.G.)] and the National Institutes of Health National Center for Advancing Translational Sciences [Award UL1-TR000058 (to D.A.G.)]. The Virginia Commonwealth University Flow Cytometry and Imaging Shared Resource Facility is supported in part by the National Institutes of Health National Cancer Institute [Grant P30-CA16059]. D.A.G. is also supported by the American Cancer Society [Institutional Research Grant].
↵
This article has supplemental material available at molpharm.aspetjournals.org.
- Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|